M&A Deal Summary

PHCHD Acquires Thermo Fisher Scientific - Anatomical Pathology Business

On January 29, 2019, PHCHD acquired medical products company Thermo Fisher Scientific - Anatomical Pathology Business from Thermo Fisher Scientific for 1.1B USD

Acquisition Highlights
  • This is PHCHD’s 1st transaction in the Medical Products sector.
  • This is PHCHD’s largest (disclosed) transaction.
  • This is PHCHD’s 1st transaction in the United States.
  • This is PHCHD’s 1st transaction in Massachusetts.

M&A Deal Summary

Date 2019-01-29
Target Thermo Fisher Scientific - Anatomical Pathology Business
Sector Medical Products
Buyer(s) PHCHD
Sellers(s) Thermo Fisher Scientific
Deal Type Divestiture
Deal Value 1.1B USD

Target

Thermo Fisher Scientific - Anatomical Pathology Business

Waltham, Massachusetts, United States
Thermo Fisher Scientific, Inc. - Anatomical Pathology Business is a provider of microscope slides, instruments, and consumables.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

PHCHD

Tokyo, Japan

Category Company
Founded 2014
Sector Medical Products
Employees10,300
DESCRIPTION

PHCHD is a healthcare company, that develops, manufactures sells, and services medical equipment and solutions across diabetes care, diagnostics, life sciences, and healthcare IT. PHCHD was founded in 2014 and is based in Tokyo, Japan.


DEAL STATS #
Overall 2 of 4
Sector (Medical Products) 1 of 1
Type (Divestiture) 2 of 2
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-11 Bayer AG - Bayer Diabetes-Care Unit

Leverkusen, Germany

Buy $1.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-05 MM France

Brignais, France

MM France is a distributor of materials, equipment, and consumables for anatomo cyto pathology laboratories. MM France was formed in 1987 and is based in Brignais, France.

Buy -

Seller(S) 1

SELLER

Thermo Fisher Scientific

Waltham, Massachusetts, United States

Category Company
Founded 1956
Sector Test/Measurement Equipment
Employees122,000
Revenue 42.9B USD (2023)
DESCRIPTION
Thermo Fisher's corporate headquarters in Waltham, Massachusetts.
Thermo Fisher's corporate headquarters in Waltham, Massachusetts.

Thermo Scientific is a provider of analytical instruments, laboratory equipment, software, services, consumables and reagents for better workflow solutions spanning sample preparation, sample analysis, and data interpretation. Thermo Fisher Scientific was founded in 1956 and is based in Waltham, Massachusetts.


DEAL STATS #
Overall 8 of 8
Sector (Medical Products) 1 of 1
Type (Divestiture) 7 of 7
State (Massachusetts) 2 of 2
Country (United States) 6 of 6
Year (2019) 1 of 1
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-03-16 IntegenX

Pleasanton, New Jersey, United States

IntegenX, Inc. is a developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics and biodefense applications. IntegenX, Inc. was established in 2003 and is based in Pleasanton, New Jersey.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-24 Brammer Bio

Cambridge, Massachusetts, United States

Brammer Biopharmaceuticals LLC was founded early in 2015 to create a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO) to enable large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. With the in-depth biologics manufacturing knowledge and expertise of founders Mark Bamforth (CEO) and Steven Kasok (CFO), previously cofounders of Gallus Biopharmaceuticals, now as Brammer Bio, the company is positioned to accelerate the development of these important emerging technologies.

Buy $1.7B